Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Tango Therapeutics (NASDAQ: TNGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-three research firms that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Alnylam Pharmaceuticals (NASDAQ: ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook. Speaking at the Morgan Stanley Global Healthcare Conference, Chief Executive Officer Yvonne Greenstreet said Alnylam's TTR franchise